Other News Releases in Biotechnology
ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries
Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category
American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
Other News Releases in Trade Show News
River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries
ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries
U.S.-China Business Summit to Host World's Largest Symposium for Americans, Chinese
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
See more news releases in: Biotechnology, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Trade Show News
Cell Therapeutics, Inc. (CTI) to Present at 8th Annual BIO Investor Forum
SEATTLE, Oct. 26 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management will present at the 8th Annual Biotechnology Industry Organization (BIO) Investor Forum. The conference will be held October 28-29, 2009, at the Palace Hotel in San Francisco. CTI will present on Thursday, October 29 at 10:00 a.m. Pacific Time. The conference will be webcast live with slides and available for replay after the presentation. The webcast can be accessed at www.celltherapeutics.com.
BIO CEO & Investor Conference
CTI Presentation: Thursday, October 29, 2009
10:00 a.m. Pacific /1:00 p.m. Eastern/7:00 p.m. Central European
Audio webcast with slides at www.celltherapeutics.com
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
F: 206.272.4434
E: deramian@ctiseattle.com
www.celltherapeutics.com/press_room
Investors Contact:
Ed Bell
T: 206.272.4345
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
www.celltherapeutics.com/investors
SOURCE Cell Therapeutics, Inc.